Breaking News Instant updates and real-time market news.

ATRC

AtriCure

$17.99

-0.4 (-2.18%)

08:13
01/08/18
01/08
08:13
01/08/18
08:13

AtriCure sees Q4 revenue approximately $46.1M, consensus $45.2M

Preliminary and unaudited revenue for fourth quarter 2017 is expected to be approximately $46.1 million, reflecting growth of approximately 12% over the fourth quarter of 2016. Based on this preliminary estimate, revenue from U.S. customers is expected to be $36.2 million, reflecting growth of 11% and revenue from international customers is expected to be approximately $9.9 million, an increase of 16% as reported and 10% on a constant currency basis. Preliminary revenue for full year 2017 is expected to be $174.7 million, reflecting growth of approximately 13% over full year 2016. Adjusted EBITDA loss (a non-GAAP measure consistently calculated as in previous releases1) for the full year 2017 is currently estimated to be in the previously communicated range of $4 to $6 million.

  • 26

    Feb

ATRC AtriCure
$17.99

-0.4 (-2.18%)

05/30/17
PIPR
05/30/17
INITIATION
Target $26
PIPR
Overweight
AtriCure assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Matt O'Brien assumed coverage of AtriCure with an Overweight rating and $26 price target. The company offers a "unique" way to play some fast growth areas within the large coronary market, the analyst contends.
07/17/17
ADAM
07/17/17
NO CHANGE
ADAM
M&A in med-tech space will accelerate, says Canaccord
Canaccord analyst Jason Mills remains cautious in the med-tech space but believes M&A will continue to be a major theme. He noted the sector is trading at peak levels and recommends trading around core positions and looking for pullbacks to average down in favorite names. He said the most likely takeout names, in this order, are, Nevro (NVRO), AtriCure (ATRC), NxStage Medical (NXTM), iRhythm (IRTC), and Penumbra (PEN).
11/02/17
PIPR
11/02/17
NO CHANGE
Target $24
PIPR
Overweight
AtriCure weakness a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien recommends using the post-earnings weakness in shares of AtriCure as a buying opportunity. The lowered sales outlook is largely the result of a spillover of deferrals from physician disruptions and fires in California, O'Brien tells investors in a post-earnings research note. The analyst views the headwinds as transitory and believes AtriCure can reaccelerate growth into 2018. He lowered his price target for the shares to $24 from $26 and maintains an Overweight rating on the name.
12/10/17
PIPR
12/10/17
NO CHANGE
Target $24
PIPR
Overweight
Piper Jaffray remains bullish on AtriCure, sees potential acceleration in 2020
Piper Jaffray analyst Matt O'Brien notes that he hosted investor meeting with AtriCure's CFO Andy Wade. Looking longer-term, the analyst believes the results of the Converge trial and a sub-x Clip might result in accelerating growth starting in 2020, which he believes would push shares much higher. Consequently, O'Brien encourages investors to start or build positions in this "compelling franchise." He reiterates an Overweight rating and $24 price target on the shares.

TODAY'S FREE FLY STORIES

PG

Procter & Gamble

09:19
01/23/18
01/23
09:19
01/23/18
09:19
Hot Stocks
Procter & Gamble says commodity costs have moved up this year »

Says seeing some growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 16

    Feb

PXD

Pioneer Natural

09:19
01/23/18
01/23
09:19
01/23/18
09:19
Recommendations
Pioneer Natural analyst commentary  »

Pioneer Natural price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

TYL

Tyler Technologies

09:18
01/23/18
01/23
09:18
01/23/18
09:18
Hot Stocks
Tyler Technologies selected by Orlando, Florida for public safety solution »

Tyler Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

PE

Parsley Energy

09:18
01/23/18
01/23
09:18
01/23/18
09:18
Recommendations
Parsley Energy analyst commentary  »

Parsley Energy price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 15

    May

SPX

S&P 500

, VIX

Volatility Index S&P 500 Options

09:18
01/23/18
01/23
09:18
01/23/18
09:18
Options
Overnight activity included 92 trades in SPX and 25 trades in VIX »

92 trades were executed…

SPX

S&P 500

VIX

Volatility Index S&P 500 Options

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

, LOGI

Logitech

$37.58

0.25 (0.67%)

09:17
01/23/18
01/23
09:17
01/23/18
09:17
Hot Stocks
On The Fly: Pre-market Movers »

UP AFTER EARNINGS:…

VZ

Verizon

LOGI

Logitech

$37.58

0.25 (0.67%)

JNJ

Johnson & Johnson

NFLX

Netflix

$227.58

7.12 (3.23%)

HBAN

Huntington Bancshares

$16.03

0.22 (1.39%)

KMB

Kimberly-Clark

RMD

ResMed

AMTD

TD Ameritrade

$55.88

0.71 (1.29%)

ATI

Allegheny Technologies

TSLA

Tesla

$351.56

1.54 (0.44%)

AAPL

Apple

$177.00

-1.46 (-0.82%)

PG

Procter & Gamble

ADMS

Adamas Pharmaceuticals

$40.79

2.6 (6.81%)

GPRO

GoPro

$6.30

0.01 (0.16%)

TWTR

Twitter

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 30

    Jan

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 08

    Feb

  • 16

    Feb

  • 16

    Feb

  • 28

    Feb

  • 08

    Mar

  • 24

    Jan

NBL

Noble Energy

09:16
01/23/18
01/23
09:16
01/23/18
09:16
Recommendations
Noble Energy analyst commentary  »

Noble Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

JNJ

Johnson & Johnson

09:16
01/23/18
01/23
09:16
01/23/18
09:16
Hot Stocks
Johnson & Johnson sees apalutamide approval in 2018 »

Johnson & Johnson CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

ABEO

Abeona Therapeutics

$14.85

0.25 (1.71%)

09:16
01/23/18
01/23
09:16
01/23/18
09:16
Initiation
Abeona Therapeutics initiated  »

Abeona Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

EOG

EOG Resources

09:15
01/23/18
01/23
09:15
01/23/18
09:15
Recommendations
EOG Resources analyst commentary  »

EOG Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

FANG

Diamondback Energy

$132.21

4.64 (3.64%)

09:13
01/23/18
01/23
09:13
01/23/18
09:13
Recommendations
Diamondback Energy analyst commentary  »

Diamondback Energy price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

09:13
01/23/18
01/23
09:13
01/23/18
09:13
Hot Stocks
Twitter drops as COO Anthony Noto resigns to become SoFi CEO »

Shares of Twitter (TWTR)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

AMRN

Amarin

$4.04

0.07 (1.76%)

09:12
01/23/18
01/23
09:12
01/23/18
09:12
Recommendations
Amarin analyst commentary  »

Amarin shares have room…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DVN

Devon Energy

09:12
01/23/18
01/23
09:12
01/23/18
09:12
Recommendations
Devon Energy analyst commentary  »

Devon Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

TWTR

Twitter

09:12
01/23/18
01/23
09:12
01/23/18
09:12
Technical Analysis
Technical Take: Twitter drops on departure of COO Anthony Noto »

Shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

CLR

Continental Resources

09:11
01/23/18
01/23
09:11
01/23/18
09:11
Recommendations
Continental Resources analyst commentary  »

Continental Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

09:10
01/23/18
01/23
09:10
01/23/18
09:10
Recommendations
Halliburton analyst commentary  »

Halliburton price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CXO

Concho Resources

$160.41

4.22 (2.70%)

09:10
01/23/18
01/23
09:10
01/23/18
09:10
Recommendations
Concho Resources analyst commentary  »

Concho Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

VZ

Verizon

$53.46

1.55 (2.99%)

09:09
01/23/18
01/23
09:09
01/23/18
09:09
Technical Analysis
Technical Take: Verizon trades higher after results »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

ANAB

AnaptysBio

$114.78

-0.135 (-0.12%)

09:08
01/23/18
01/23
09:08
01/23/18
09:08
Recommendations
AnaptysBio analyst commentary  »

AnaptysBio price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XEC

Cimarex Energy

$126.80

2.76 (2.23%)

09:08
01/23/18
01/23
09:08
01/23/18
09:08
Recommendations
Cimarex Energy analyst commentary  »

Cimarex Energy price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 15

    Feb

DGX

Quest Diagnostics

$103.57

0.51 (0.49%)

09:08
01/23/18
01/23
09:08
01/23/18
09:08
Hot Stocks
Quest Diagnostics to acquire MedXM for undisclosed amount »

Quest Diagnostics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

VZ

Verizon

$53.46

1.55 (2.99%)

09:07
01/23/18
01/23
09:07
01/23/18
09:07
Hot Stocks
Breaking Hot Stocks news story on Verizon »

Verizon says FY18 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

SLB

Schlumberger

$79.79

3.37 (4.41%)

09:06
01/23/18
01/23
09:06
01/23/18
09:06
Recommendations
Schlumberger analyst commentary  »

Schlumberger price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$60.72

2.52 (4.33%)

09:06
01/23/18
01/23
09:06
01/23/18
09:06
Recommendations
Anadarko analyst commentary  »

Anadarko price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.